OSAHS患儿扁桃体和腺样体术后免疫功能的变化

目的 阻塞性睡眠呼吸暂停低通气综合征(OSAHS)是耳鼻咽喉科的一种常见病，儿童发病率呈上升趋势，调查显示儿童OSAHS发生率为4%~5%，2~6岁是发病的高峰期。OSAHS不仅严重影响儿童的睡眠质量，还会引起儿童生长发育迟缓、智力缺陷等一系列不良反应，OSAHS患儿的主要病因是扁桃体和/或腺样体肥大，因此最有效的治疗方法是扁桃体切除术和腺样体切除术。而扁桃体和腺样体是儿童淋巴组织系统的重要组成部分，在机体的防御和保护功能中发挥着重要作用。手术治疗OSAHS是否影响儿童的免疫功能目前存在争议。一些学者认为扁桃体切除和腺样体切除后儿童的免疫力降低，而另一些学者认为OSAHS儿童的免疫力在手术后保持不变，甚至比手术前有所提高。本文就儿童OSAHS手术前后免疫指标的变化作一综述。     

Comparison of the practicability of ultrasound and spiral computed tomography in the diagnosis of colon cancer: A protocol for systematic review and meta-analysis

Background:Colon cancer is a common malignant tumor of the gastrointestinal tract. Therefore, a clear diagnosis is particularly important for the treatment of colon cancer. Ultrasound and spiral computed tomography (CT) can both be used in the diagnosis, but each has its own advantages and disadvantages, which could cause confusion in clinical choice. The purpose of this study was to systematically evaluate the practicability of spiral CT and ultrasound in the diagnosis of colon cancer.Methods:A systematic search was performed by retrieving on English databases (PubMed, Embase, Web of Science, the Cochrane Library) and Chinese databases (CNKI, Wanfang, Weipu [VIP], CBM). Besides, manually search for Google and Baidu academic of diagnostic experimental study of ultrasound and spiral CT in the diagnosis of Colon Cancer. The retrieval time limit was from the establishment of the database to October 2020. Two researchers independently extracted and evaluated the quality of the data in the included study. A meta-analysis was performed using Meta Disc1.4 and RevMan5.3 software.Results:Sensitivity, specificity, positive Likelihood ratio, negative likelihood ratio, and diagnostic odds ratio were used to determine the diagnostic efficacy of ultrasonography and helical CT in colorectal cancer.Conclusions:This study will compare the practicability of CT and ultrasound in the diagnosis of colon cancer and provide reliable evidence-based basis for clinicians to choose the appropriate or best evidence-based basis.Ethics and dissemination:The private information from individuals will not be published. This systematic review also will not involve endangering participant rights. Ethical approval is not required. The results may be published in a peer-reviewed journal or disseminated in relevant conferences.OSF Registration number:DOI 10.17605/OSF.IO/WAJHQ     

The prognostic role of tumour‐infiltrating lymphocytes in oral squamous cell carcinoma: A meta‐analysis

It has been suggested that tumour‐infiltrating lymphocytes (TILs) are associated with the progression of oral squamous cell carcinoma (OSCC). However, the prognostic value of TILs is inconclusive due to the heterogeneity of immune cells within the tumour microenvironment. In this meta‐analysis, we aimed to assess the prognostic value of TILs in OSCC. The PubMed, Cochrane, Embase, Scopus and Web of Science databases were searched up to April 20, 2019, and 33 studies were ultimately included in this meta‐analysis. Our pooled meta‐analysis showed that high infiltration of CD8⁺ TILs, CD45RO⁺ TILs and CD57⁺ TILs favoured better overall survival (OS). However, high infiltration of CD68⁺ macrophages and CD163⁺ macrophages was associated with poor prognosis in OSCC. These findings suggest that CD8⁺ TILs, CD45RO⁺ TILs, CD57⁺ TILs, CD68⁺ macrophages and CD163⁺ macrophages might serve as novel prognostic factors and therapeutic targets in OSCC.     

微小RNA在皮肤鳞状细胞癌中的研究进展

皮肤鳞状细胞癌(cSCC)是角质形成细胞来源的恶性肿瘤之一。转录组是特定条件下细胞内全部转录产物的总和,包括编码mRNA和非编码RNA。研究发现,与正常细胞相比,鳞癌细胞在基因转录水平和模式上存在很大差异,具有不同转录表达谱。微小RNA(miRNA)可通过抑制转录产物的翻译,从而调控靶基因的表达,影响cSCC细胞的增殖、分化和凋亡等病理过程。越来越多的研究表明,miRNAs作为cSCC诊断、预测预后和治疗靶点的生物标志物,在临床上具有广阔的应用前景。本文通过回顾分析cSCC的miRNA表达谱,主要对其中经实验证实表达上调和下调的miRNAs在cSCC中的研究进展作一综述。     

早期乳腺癌后续强化辅助内分泌治疗(MA-17研究结果解读)

1乳腺癌内分泌治疗:他莫昔芬的益处和局限性他莫昔芬(TAM)是最常用的乳腺癌内分泌治疗的药物,关于TAM在早期乳癌术后预防复发转移的辅助治疗阶段中应用,最为权威的结论来自发表在Lancet上、对5 5个临床试验共计37 000例患者的综合回顾报告,目前TAM在乳癌辅助治疗中应用的基本共识有:①辅助内分泌治疗的决定因素为激素受体(ER/PR)状况,ER阳性者效果最好,部分ER、阴性PR阳性的患者也可以使用TAM,但ER阴性患者辅助治疗用TAM不能改善生存;②目前认为TAM合适的服药时间为5年,可以显著降低复发风险12%,提高生存率9%。至于再延长用药…     

Additional bedtime H2‐receptor antagonist for the control of nocturnal gastric acid breakthrough: A Cochrane systematic review

OBJECTIVES: To assess the effectiveness and safety of additional bedtime H₂‐receptor antagonists (H₂RAs) in suppressing nocturnal gastric acid breakthrough (NAB) via a systematic review. METHODS: Eligible trials were identified by searching the Cochrane Central Register of Controlled Trials (CENTRAL) (Cochrane Library Issue 2, 2004), MEDLINE (January 1966–June 2004), EMBASE (January 1980–June 2004) and CINAHL (January 1982–June 2004). Additional hand‐searching was conducted on the proceedings of correlated conferences, eight important Chinese journals and references of all included trials. All randomized controlled trials evaluating H₂RAs for the control of NAB were eligible for inclusion. The systematic review was conducted using methods recommended by The Cochrane Collaboration. RESULTS: Only two randomized crossover studies, comprising 32 participants, met the inclusion criteria. Because the design, dosage and duration of the treatments were different between the studies, it was not possible to conduct meta‐analysis. There were no consistent conclusions found between the two included studies in evaluating H₂RAs for the control of NAB. CONCLUSIONS: No implications for practice at this stage can be concluded. Appropriately designed large‐scale randomized controlled trials with long‐term follow up are needed to determine the effects of additional bedtime H₂RAs in suppressing NAB.     

新型雌激素受体β信号通路调节因子的分离及鉴定

目的：利用酵母双杂交技术筛选与ERβ相互作用的蛋白，为进一步研究ERβ的功能奠定基础。方法：从乳腺cDNA文库中钓取ERβ-AF1 cDNA，构建诱饵蛋白载体pAS2-1-ERβ—AF1，利用酵母双杂交筛选技术，在乳腺cDNA文库中筛选与ERβ-AF1相互作用的蛋白。将含有pACT2-候选基因的酵母菌与含有pAS2—1-ERp—AF1的酵母菌进行交配实验，利用LacZ报告基因检测ERβ—AF1与候选蛋白之间是否存在相互作用。然后将ERp—AF1和候选蛋白分别构建到pGEx-KG和pET-28a上，并纯化GST-ERβ-AF1和His-侯选蛋白融合蛋白，利用GST沉淀实验进一步验证ERβ-AF1和候选蛋白的体外相互作用。结果：所获取的候选蛋白为CTGF，是CCN多肽家族成员。交配实验表明，CTGF与ERβ-AF1特异相互作用，而不与空载体或BRCT1对照相互作用。GST沉淀实验进一步验证，CTGF与ERβ、ERα均存在相互作用，但与CTGF同源性较高的NOV蛋白却不与ERβ、ERa结合。结论：CTGF和ERβ存在特异的相互作用。     

纤维素分解菌BSX5的分离、鉴定及产酶条件

利用透明圈法从袋装降解的笋干中分离到一株分解纤维素的细菌菌株. 该菌株呈长杆状、革兰氏染色为阳性、产芽孢,命名为BSX5.其生理生化特征和16S rDNA序列同源性分析,发现该菌株与Bacillus subtilis的同源性为99%,系统发育树分析与Bacillus subtilis遗传关系最近,确定该菌株为Bacillus subtilis. 采用以3,5-二硝基水杨酸（DNS）为显色剂、羧甲基纤维素钠（CMC-Na）为底物,测定不同培养条件下BSX5菌株的酶活力,结果最适产酶时间为8-12 h,最适产酶温度为50 ℃,最适产酶pH值为5.5～6.5.